MCID: CHR070
MIFTS: 40

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Categories: Neuronal diseases

Aliases & Classifications for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

MalaCards integrated aliases for Chronic Inflammatory Demyelinating Polyradiculoneuropathy:

Name: Chronic Inflammatory Demyelinating Polyradiculoneuropathy 12 37 15 17
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 72
Polyradiculoneuropathy Chronic Inflammatory Demyelinating 55

Classifications:



External Ids:

Disease Ontology 12 DOID:5213
KEGG 37 H01527
ICD9CM 35 357.81
MeSH 44 D020277
NCIt 50 C84636
ICD10 33 G61.81
UMLS 72 C0393819

Summaries for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

KEGG : 37
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a polyneuropathy that is often disabling, with more than 50% of patients reported as having temporary disability, and about 10% eventually becoming persistently disabled. The core clinical features are a chronic progressive or relapsing and remitting, symmetrical, and sensory and motor polyradiculoneuropathy causing weakness of proximal and distal muscles. The etiology is suspected to be of autoimmune origin, and the diagnosis is typically based on clinical history, neurologic examination, electrophysiologic studies, cerebrospinal fluid (CSF) studies, and pathologic examination. CIDP often responds to immune therapies including corticosteroids, plasma exchange, and high-dose intravenous immunoglobulin (IVIg).

MalaCards based summary : Chronic Inflammatory Demyelinating Polyradiculoneuropathy, also known as polyradiculoneuropathy, chronic inflammatory demyelinating, is related to guillain-barre syndrome and neuritis. An important gene associated with Chronic Inflammatory Demyelinating Polyradiculoneuropathy is PMP22 (Peripheral Myelin Protein 22), and among its related pathways/superpathways are Allograft rejection and Interferon gamma signaling. The drugs Amifampridine and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, t cells and skin, and related phenotype is homeostasis/metabolism.

Related Diseases for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Diseases related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 217)
# Related Disease Score Top Affiliating Genes
1 guillain-barre syndrome 31.5 PMP22 MPZ ALB
2 neuritis 31.3 PMP22 MPZ IFNG
3 charcot-marie-tooth disease, demyelinating, type 1a 31.3 PMP22 MPZ
4 optic neuritis 31.2 MPZ HLA-DRB1
5 demyelinating polyneuropathy 31.2 PMP22 NFASC ALB
6 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 31.0 IL17A IFNG
7 foot drop 31.0 PMP22 MPZ
8 chronic graft versus host disease 31.0 IFNG ALB
9 neuropathy, hereditary, with liability to pressure palsies 30.9 PMP22 MPZ
10 autoimmune disease 30.9 IL17A IFNG HLA-DRB1
11 acute disseminated encephalomyelitis 30.8 MPZ HLA-DRB1
12 peripheral nervous system disease 30.6 PMP22 NFASC MPZ ALB
13 hepatitis a 30.5 IFNG ALB
14 autoimmune peripheral neuropathy 30.5 MPZ IFNB1
15 neuromyelitis optica 30.3 IL17A HLA-DRB1
16 demyelinating disease 29.9 IL17A IFNG IFNB1
17 relapsing-remitting multiple sclerosis 29.8 IL17A IFNG IFNB1
18 nervous system disease 29.7 IFNG IFNB1 ALB
19 polyradiculoneuropathy 28.9 PRF1 PMP22 NFASC MPZ IL17A IFNG
20 systemic lupus erythematosus 28.6 IL17A IFNG IFNB1 HLA-DRB1 ALB
21 multiple sclerosis 28.0 PRF1 MPZ IL17A IFNG IFNB1 HLA-DRB1
22 chronic inflammatory demyelinating polyneuropathy 12.5
23 lewis-sumner syndrome 11.9
24 chronic inflammatory demyelinating polyneuritis 11.6
25 x-linked charcot-marie-tooth disease 11.5
26 polyneuropathy 11.0
27 neuropathy 10.9
28 neuromuscular disease 10.7
29 monoclonal gammopathy of uncertain significance 10.6
30 charcot-marie-tooth hereditary neuropathy 10.6 PMP22 MPZ
31 roussy-levy hereditary areflexic dystasia 10.6 PMP22 MPZ
32 charcot-marie-tooth disease, demyelinating, type 1f 10.6 PMP22 MPZ
33 charcot-marie-tooth disease, axonal, type 2d 10.6 PMP22 MPZ
34 charcot-marie-tooth disease, demyelinating, type 1c 10.6 PMP22 MPZ
35 charcot-marie-tooth disease, x-linked dominant, 1 10.6 PMP22 MPZ
36 ataxia and polyneuropathy, adult-onset 10.6
37 cauda equina syndrome 10.6
38 charcot-marie-tooth disease, demyelinating, type 1b 10.5 PMP22 MPZ
39 charcot-marie-tooth disease, axonal, type 2b 10.5 PMP22 MPZ
40 motor peripheral neuropathy 10.5 PMP22 MPZ
41 polyradiculopathy 10.5
42 paresthesia 10.5
43 charcot-marie-tooth disease, demyelinating, type 1d 10.5 PMP22 MPZ
44 multifocal motor neuropathy 10.5
45 autonomic dysfunction 10.5
46 tremor 10.5
47 chronic beryllium disease 10.5 IFNG HLA-DRB1
48 berylliosis 10.5 IFNG HLA-DRB1
49 respiratory failure 10.4
50 eosinophilia-myalgia syndrome 10.4 IFNG HLA-DRB1

Graphical network of the top 20 diseases related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy:



Diseases related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Symptoms & Phenotypes for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

MGI Mouse Phenotypes related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.23 ALB IFNB1 IFNG IL17A MPZ NFASC

Drugs & Therapeutics for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Drugs for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 43)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amifampridine Approved, Investigational Phase 3 54-96-6
2
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
3
Glycine Approved, Nutraceutical, Vet_approved Phase 3 56-40-6 750
4 Immunoglobulin G Phase 3
5 Fingolimod Hydrochloride Phase 3
6 Neuromuscular Agents Phase 3
7 Peripheral Nervous System Agents Phase 3
8 Potassium Channel Blockers Phase 3
9 Hormones Phase 3
10 Hormone Antagonists Phase 3
11 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
12 glucocorticoids Phase 3
13 Anti-Inflammatory Agents Phase 3
14 Antineoplastic Agents, Hormonal Phase 3
15 Pharmaceutical Solutions Phase 2, Phase 3
16
Interferon beta-1a Approved, Investigational Phase 2 145258-61-3 6438354
17
rituximab Approved Phase 2 174722-31-7 10201696
18
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
19 Antibodies Phase 2
20 Immunologic Factors Phase 2
21 gamma-Globulins Phase 2
22 Immunoglobulins Phase 2
23 Immunoglobulins, Intravenous Phase 2
24 Rho(D) Immune Globulin Phase 2
25 Adjuvants, Immunologic Phase 2
26 Interferon-beta Phase 2
27 interferons Phase 2
28 Antiviral Agents Phase 2
29 Anti-Infective Agents Phase 2
30 Trace Elements Phase 2
31 Micronutrients Phase 2
32 Alpha-lipoic Acid Phase 2
33 Antioxidants Phase 2
34 Vitamins Phase 2
35 Protective Agents Phase 2
36 Vitamin B9 Phase 2
37 Nutrients Phase 2
38 Vitamin B Complex Phase 2
39 Folate Phase 2
40 Thioctic Acid Phase 2
41 Autoantibodies Phase 2
42 4-des-dimethylaminotetracycline
43 Antibodies, Anti-Idiotypic

Interventional clinical trials:

(show top 50) (show all 52)
# Name Status NCT ID Phase Drugs
1 Treatment With Gamunex 10% Intravenous Immunoglobulin (IVIg) for Patients With Demyelination and Diabetes Mellitus: A Blinded, Placebo-Controlled Crossover Pilot Study Unknown status NCT02372149 Phase 4 10% intravenous immunoglobulin (IVIg);0.9% sodium chloride
2 Randomized Study of Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP Recruiting NCT03684018 Phase 4
3 An Open-Label Trial of Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD) Withdrawn NCT01757574 Phase 4 Alemtuzumab infusion
4 Prospective, Open-Label, Phase IIIb Study Evaluating the Safety, Tolerability and Efficacy of Panzyga® in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Administered at Standard and High Infusion Rates Unknown status NCT03166527 Phase 3 Immune Globulin 10% Intravenous Solution
5 An International, Multicentre, Efficacy and Safety Study of I10E in Initial and Maintenance Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Completed NCT02293460 Phase 3 I10E
6 A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Fingolimod 0.5 mg Administered Orally Once Daily Versus Placebo in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT01625182 Phase 3 Fingolimod;Placebo Comparator
7 Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating Polyneuropathy Completed NCT00004939 Phase 3 ,4-diaminopyridine
8 A Single-arm Study to Demonstrate the Efficacy and Safety of Privigen in the Treatment of Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT01184846 Phase 3
9 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00004772 Phase 3 Immune globulin
10 Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating Neuropathy Completed NCT00004286 Phase 3 immune globulin
11 NPB-01(Intravenous Immunoglobulin) Maintenance Therapy for Patients With Chronic Inflammatory Demyelinating Polyneuropathy. Completed NCT01824251 Phase 3 NPB-01
12 Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of IGIV-Chromatography (IGIV-C), 10% Treatment in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00220740 Phase 3 Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified;Albumin (Human) 25%, United States Pharmacopeia (USP)
13 Multicenter, Open-label Extension Study to Investigate the Long-term Safety and Efficacy of IgPro20 in Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Subjects Completing Study IgPro20_3003 Completed NCT02027701 Phase 3
14 Multicentre Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg in Patients With Chronic Inflammatory Demyelinating Polyneuropathy on a One Year Follow up Completed NCT01349270 Phase 3 Immunoglobulin perfusion;Prednisone
15 Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study Completed NCT01545076 Phase 3
16 Long-Term Tolerability and Safety of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Recruiting NCT02955355 Phase 3
17 A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human), 10% (GAMMAGARD LIQUID/KIOVIG) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Recruiting NCT02549170 Phase 3
18 International, Multicentre, Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Extension of PRISM Study I10E-1302" Terminated NCT02317562 Phase 3 I10E
19 Double-blind, Placebo-controlled, Randomised, Multicentre, Adaptive, Two-stage Phase 2/3 Study Evaluating Safety and Efficacy of Three Dosages of NewGam in CIDP Patients Terminated NCT01225276 Phase 2, Phase 3 NewGam 10%;Placebo;NewGam 10%;NewGam 10%
20 SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study Unknown status NCT02967679 Phase 1, Phase 2 MD1003
21 Randomised, Double-blinded, Placebo-controlled Trial of Subcutaneous Immunoglobulin Treatment in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT01017159 Phase 2 Subcutaneous immunoglobulin
22 A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Safety and Efficacy of AVONEX When Used in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT00099489 Phase 2 Interferon Beta-1a
23 Lipoic Acid for Chronic Inflammatory Demyelinating Polyneuropathy—A Randomized, Double-Blind, Placebo Controlled Pilot Study Completed NCT00962429 Phase 2 lipoic acid
24 The Efficacy of High-Dose Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00001287 Phase 2 intravenous immunoglobulin (IVIg)
25 Early Onset Immunotherapy by Intravenous Immunoglobulin in Well-characterized Onconeural-antibody-positive Paraneoplastic Neurological Syndromes Completed NCT02343211 Phase 2 Immunoglobulin
26 A Multicenter, Randomized, Subject-Blind, Investigator-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Recruiting NCT03861481 Phase 2 Rozanolixizumab
27 The Evaluation of Efficacy and Safety of Rituximab (Genetical Recombination) in Refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients With Immunoglobulin G4 (IgG4) Autoantibodies in the Exploratory Clinical Trial Recruiting NCT03864185 Phase 2
28 Non-myeloablative Autologous Hematopoietic Stem Cell Transplantation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy: A Phase II Trial Active, not recruiting NCT00278629 Phase 2
29 An Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Not yet recruiting NCT04051944 Phase 2 Rozanolixizumab
30 Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy Withdrawn NCT02574962 Phase 2 H.P. Acthar® Gel
31 A Phase II Trial of High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy Withdrawn NCT01236456 Phase 2 Cyclophosphamide
32 A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, FIRST-IN-HUMAN TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF PF-06755347 AFTER SINGLE ASCENDING INTRAVENOUS INFUSIONS TO HEALTHY ADULT MALE PARTICIPANTS Recruiting NCT03275740 Phase 1 PF-06755347;Placebo comparator
33 sCD163 & CD19 as Candidate Biomarkers in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - A Study of sCD163 in the Cerebrospinal Fluid Unknown status NCT02271724
34 Magnetic Resonance Imaging and Ultrasound Imaging of Peripheral Nerves in Patients Treated With Immunoglobulin in Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Completed NCT02017769
35 "Clinical Study of Intravenous Immunoglobulin Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy" Completed NCT00305266 intravenous gammaglobulin
36 MRI of the Brachial Plexus and Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Assessment of DTI-derived Measurements at 3.0-T Completed NCT03460951
37 Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT01379833
38 Effect of Resistance and Aerobic Exercise on Muscle Strength, Aerobic Capacity and Quality of Life in Patients Treated With Immunoglobulin for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) or Multifocal Motor Neuropathy (MMN) Completed NCT02121678
39 The Influence of Immunoglobulin Dosage and Administration on Development of Hemolytic Anemia and Variation on Muscle Strength in Patients With CIDP and MMN Completed NCT02111590 Immunoglobulins
40 Magnetic Resonance Diagnostics of Diabetic Peripheral Neuropathy Completed NCT01847937
41 Biomarker to Predict the Response to Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients: a Transcriptomic Study Recruiting NCT02629796
42 A Multicenter Pilot Study to Determine Criteria for Evaluating the Effectiveness of Two Comparative Monitoring Methods in the Management of Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Receiving Home-based Treatment With IVIg (Privigen®) Recruiting NCT03779828
43 A Clinical Trial to Assess the Safety of a Novel Scaffold Biomaterial Recruiting NCT03584022
44 Descriptive Analysis of Morphological Aspects of Nerve by Ultra-high Frequency Ultrasound (30-50MHZ) in Demyelinating Neuropathies: Inflammatory Demyelinating Polyneuropathy Chronic (IPDC), Neuropathy Multifocal Motor Block of Conducting (NMMBC) and Neuropathy With Antibody A MAG Recruiting NCT03008733
45 Pain In Neuropathy Study Recruiting NCT02672059
46 Identification of the Mechanisms of Action of Intravenous Immunoglobulins in CIDP by Analysis of the Genetic Expression Profile in Blood Mononuclear Cells Active, not recruiting NCT02404298 IVIg
47 Study of Electrical Prognostic Factors of Response to Intravenous Immunoglobulin Treatment in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Active, not recruiting NCT03967899
48 A Study of Subcutaneous Immunoglobulin as Chronic Treatment for Patients With Chronic Inflammatory Demyelinating Polyneuropathy Active, not recruiting NCT02465359 Immune Globulin Subcutaneous (Human)
49 Intravenous Immunoglobulin (IVIg) Treatment-Related Fluctuations in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients Using Daily Grip Strength Measurements (GRIPPER) Active, not recruiting NCT02414490 Intravenous Immunoglobulin
50 Exploratory Study of Predictive Markers of the Therapeutic Response in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Treated With Intravenous Immunoglobulin Not yet recruiting NCT02892890

Search NIH Clinical Center for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Immunoglobulins, Intravenous

Genetic Tests for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Anatomical Context for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

MalaCards organs/tissues related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy:

41
Spinal Cord, T Cells, Skin, Brain, Testes, Tongue, Kidney

Publications for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Articles related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy:

(show top 50) (show all 796)
# Title Authors PMID Year
1
T cell reactivity to P0, P2, PMP-22, and myelin basic protein in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. 9 38
16170091 2005
2
Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10. 9 38
11912115 2002
3
P0 protein is a target antigen in chronic inflammatory demyelinating polyradiculoneuropathy. 9 38
11558784 2001
4
Anti-PMP22 antibodies in patients with inflammatory neuropathy. 9 38
10713353 2000
5
Randomized trial of interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. 9 38
10408537 1999
6
Serial nerve ultrasound and motor nerve conduction studies in chronic inflammatory demyelinating polyradiculoneuropathy. 38
31206194 2019
7
Defining chronic inflammatory demyelinating polyradiculoneuropathy subtypes. 38
31227561 2019
8
Alternatives to intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy. 38
31372734 2019
9
Clinicopathological characteristics of subtypes of chronic inflammatory demyelinating polyradiculoneuropathy. 38
31227562 2019
10
Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. 38
31076244 2019
11
Validation of the Serbian version of I-RODS in patients with chronic inflammatory demyelinating polyradiculoneuropathy. 38
31397933 2019
12
Clinical factors, diagnostic delay and residual deficits in chronic inflammatory demyelinating polyradiculoneuropathy. 38
31410938 2019
13
Does cerebrospinal fluid analysis have a meaningful role in the diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy? 38
31090075 2019
14
Risk factors for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): antecedent events, lifestyle and dietary habits. Data from the Italian CIDP Database. 38
31325350 2019
15
Patient hand and artistic depiction of chronic inflammatory demyelinating polyradiculoneuropathy. 38
31262986 2019
16
POEMS Syndrome: 2019 Update on diagnosis, risk-stratification, and management. 38
31012139 2019
17
Autoantibodies in chronic inflammatory demyelinating polyradiculoneuropathy. 38
31306213 2019
18
Therapeutic apheresis in neurological, nephrological and gastrointestinal diseases. 38
31029610 2019
19
Immunoglobulin Treatment in Neuromuscular Medicine. 38
31135621 2019
20
Efficacy and Safety of Octagam® in Patients With Chronic Inflammatory Demyelinating Polyneuropathy. 38
30903535 2019
21
Chronic immune sensorimotor polyradiculopathy: Report of a case series. 38
30697760 2019
22
Chronic Acquired Polyneuropathy Patient Reported Index (CAPPRI) in chronic inflammatory demyelinating polyradiculoneuropathy. 38
31209940 2019
23
Diagnosis and treatment response in the asymmetric variant of chronic inflammatory demyelinating polyneuropathy. 38
31090121 2019
24
One-year follow-up study of neuropathic pain in chronic inflammatory demyelinating polyradiculoneuropathy. 38
30973184 2019
25
Pain in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta-Analysis. 38
31201680 2019
26
Tongue tremor in neurofascin-155 IgG4 seropositive chronic inflammatory polyradiculoneuropathy. 38
30713112 2019
27
Polyneuropathies and chronic inflammatory demyelinating polyradiculoneuropathy in multiple sclerosis. 38
30870805 2019
28
High salt diet ameliorates functional, electrophysiological and histological characteristics of murine spontaneous autoimmune polyneuropathy. 38
30468863 2019
29
Atypical Clinical Presentations of Pediatric Acute Immune-Mediated Polyneuropathy. 38
30674221 2019
30
Six-minute walk test is reliable and sensitive in detecting response to therapy in CIDP. 38
30721354 2019
31
FTY720 controls disease severity and attenuates sciatic nerve damage in chronic experimental autoimmune neuritis. 38
30825874 2019
32
Lumbosacral radiculoplexus neuropathy: Incidence and the association with diabetes mellitus. 38
30760636 2019
33
Intravenous immunoglobulins in patients with clinically suspected chronic immune-mediated neuropathy. 38
30623818 2019
34
Expanded teased nerve fibre pathological conditions in disease association. 38
30385486 2019
35
Proposal of new clinical diagnostic criteria for POEMS syndrome. 38
30279213 2019
36
Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database. 38
30297520 2019
37
Incidence and Prevalence of Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta-Analysis. 38
30669140 2019
38
Correction: Absence of pathogenic mutations in CD59 in chronic inflammatory demyelinating polyradiculoneuropathy. 38
30995265 2019
39
Peripheral nervous system involvement in systemic lupus erythematosus: a review of the evidence. 38
29846158 2019
40
Patterns of peripheral neuropathy in Sjogren's syndrome in a tertiary care hospital from South India. 38
30688241 2019
41
Peripheral Demyelinating Diseases: From Biology to Translational Medicine. 38
30941082 2019
42
Simultaneous MR neurography and apparent T2 mapping in brachial plexus: Evaluation of patients with chronic inflammatory demyelinating polyradiculoneuropathy. 38
30266626 2019
43
Are the treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) effective and safe? - A Cochrane Overview summary with commentary. 38
31256085 2019
44
Absence of pathogenic mutations in CD59 in chronic inflammatory demyelinating polyradiculoneuropathy. 38
30794663 2019
45
Neuroimaging markers of clinical progression in chronic inflammatory demyelinating polyradiculoneuropathy. 38
31244899 2019
46
Lumbar plexus in patients with chronic inflammatory demyelinating polyradiculoneuropathy: evaluation with simultaneous T2 mapping and neurography method with SHINKEI. 38
30160180 2018
47
Anti-neurofascin autoantibody and demyelination. 38
30582947 2018
48
Rituximab in chronic inflammatory demyelinating polyradiculoneuropathy with associated diseases. 38
30203907 2018
49
Nerve and skin biopsy in neuropathies. 38
30080717 2018
50
Immune-mediated neuropathies. 38
30310069 2018

Variations for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Expression for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Search GEO for disease gene expression data for Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

Pathways for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

GO Terms for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Cellular components related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 myelin sheath GO:0043209 8.32 MPZ

Biological processes related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 defense response to virus GO:0051607 9.54 PRF1 IFNG IFNB1
2 cell death GO:0008219 9.43 PMP22 IL17A
3 peripheral nervous system development GO:0007422 9.4 PMP22 NFASC
4 positive regulation of osteoclast differentiation GO:0045672 9.32 IL17A IFNG
5 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.26 IFNG IFNB1
6 positive regulation of interleukin-23 production GO:0032747 9.16 IL17A IFNG
7 positive regulation of killing of cells of other organism GO:0051712 8.96 PRF1 IFNG
8 myelination GO:0042552 8.8 PMP22 NFASC MPZ

Molecular functions related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.8 IL17A IFNG IFNB1

Sources for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....